In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
Executives at the Minnesota-run medtech giant have banked on the high blood pressure-curbing renal denervation system to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback